Roche awaits positive news from EPO (European Patent Office) on PCR (polymerase chain reaction) patents
This article was originally published in Clinica
Executive Summary
Roche says it has moved forward in its years-old battle to secure rights to its polymerase chain reaction (PCR) patents in various markets. Its two foundational patents have been subject to challenges in the US, and in Europe, where last week the European Patent Office's board of appeals signalled to Roche its intention to maintain the '184 and '362 patents, against a consortium of cross-industry companies from the healthcare and agriculture industries that had launched an opposition to the patents in 1995.